The psychopharmacology of Huntington disease
(2019) 165. p.179-189- Abstract
- Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded cytosine–adenine–guanine triplet repeat in the huntingtin gene. The current diagnosis is based on the presence of typical motor signs in combination with a positive gene test. The motor onset of the disease is usually between 30 and 50 years of age, and the disease then progresses over around 20 more years. Nonmotor symptoms and signs such as cognitive decline, metabolic dysfunction, sleep disturbances, as well as psychiatric symptoms are common and can occur many years before motor onset. Psychiatric symptoms include irritability, apathy, depression, anxiety, and OCD. Although there exist no disease-modifying treatment, available pharmacologic drugs... (More)
- Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded cytosine–adenine–guanine triplet repeat in the huntingtin gene. The current diagnosis is based on the presence of typical motor signs in combination with a positive gene test. The motor onset of the disease is usually between 30 and 50 years of age, and the disease then progresses over around 20 more years. Nonmotor symptoms and signs such as cognitive decline, metabolic dysfunction, sleep disturbances, as well as psychiatric symptoms are common and can occur many years before motor onset. Psychiatric symptoms include irritability, apathy, depression, anxiety, and OCD. Although there exist no disease-modifying treatment, available pharmacologic drugs often offer significant symptom relief and improve quality of life. Today, there are only two drugs that are approved by the US Food and Drug Association for the treatment of HD. These are the dopamine-depleting drugs tetrabenazine and deutetrabenazine that both target motor symptoms. The current status of best clinical practice for HD is based on expert opinions as well as evidence and/or experience of treating similar symptoms in other conditions. In this chapter, we provide an overview of the complex clinical manifestations of HD and the commonly used psychopharmacologic treatments. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1493510b-d6e8-460f-8d76-cc3c51aea2ff
- author
- Petersén, Åsa LU and Weydt, Patrick
- organization
- publishing date
- 2019
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- host publication
- Handbook of Clinical Neurology : Psychopharmacology of Neurologic Disease - Psychopharmacology of Neurologic Disease
- editor
- Reus, V and Lindqvist, D
- volume
- 165
- pages
- 179 - 189
- external identifiers
-
- pmid:31727211
- scopus:85074704375
- DOI
- 10.1016/B978-0-444-64012-3.00010-1
- language
- English
- LU publication?
- yes
- id
- 1493510b-d6e8-460f-8d76-cc3c51aea2ff
- date added to LUP
- 2020-04-29 12:15:52
- date last changed
- 2022-05-12 02:04:55
@inbook{1493510b-d6e8-460f-8d76-cc3c51aea2ff,
abstract = {{Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded cytosine–adenine–guanine triplet repeat in the huntingtin gene. The current diagnosis is based on the presence of typical motor signs in combination with a positive gene test. The motor onset of the disease is usually between 30 and 50 years of age, and the disease then progresses over around 20 more years. Nonmotor symptoms and signs such as cognitive decline, metabolic dysfunction, sleep disturbances, as well as psychiatric symptoms are common and can occur many years before motor onset. Psychiatric symptoms include irritability, apathy, depression, anxiety, and OCD. Although there exist no disease-modifying treatment, available pharmacologic drugs often offer significant symptom relief and improve quality of life. Today, there are only two drugs that are approved by the US Food and Drug Association for the treatment of HD. These are the dopamine-depleting drugs tetrabenazine and deutetrabenazine that both target motor symptoms. The current status of best clinical practice for HD is based on expert opinions as well as evidence and/or experience of treating similar symptoms in other conditions. In this chapter, we provide an overview of the complex clinical manifestations of HD and the commonly used psychopharmacologic treatments.}},
author = {{Petersén, Åsa and Weydt, Patrick}},
booktitle = {{Handbook of Clinical Neurology : Psychopharmacology of Neurologic Disease}},
editor = {{Reus, V and Lindqvist, D}},
language = {{eng}},
pages = {{179--189}},
title = {{The psychopharmacology of Huntington disease}},
url = {{http://dx.doi.org/10.1016/B978-0-444-64012-3.00010-1}},
doi = {{10.1016/B978-0-444-64012-3.00010-1}},
volume = {{165}},
year = {{2019}},
}